160 related articles for article (PubMed ID: 16778722)
1. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium.
Klaeffling C; Piechottka G; Daemgen-von Brevern G; Mosch G; Mani H; Luxembourg B; Lindhoff-Last E
Ther Drug Monit; 2006 Jun; 28(3):375-81. PubMed ID: 16778722
[TBL] [Abstract][Full Text] [Related]
2. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices.
Paolucci F; Frasa H; Van Aarle F; Capdevla A; Clavies MC; van Dinther T; Donat F; Hendriks Y; van den Heuvel M; Nadal T; Lagrange F; Necciari J; Perez Y
Clin Lab; 2003; 49(9-10):451-60. PubMed ID: 14572200
[TBL] [Abstract][Full Text] [Related]
3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
4. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
[TBL] [Abstract][Full Text] [Related]
5. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
[TBL] [Abstract][Full Text] [Related]
6. Automated assay for fondaparinux (Arixtra) on the Dade Behring BCS XP.
Sanfelippo MJ; Tillema VB
Am J Clin Pathol; 2009 Oct; 132(4):608-12. PubMed ID: 19762539
[TBL] [Abstract][Full Text] [Related]
7. The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
Dempfle CE; Eichner J; Suvajac N; Ahmad-Nejad P; Neumaier M; Borggrefe M
Anesth Analg; 2009 Sep; 109(3):712-6. PubMed ID: 19690236
[TBL] [Abstract][Full Text] [Related]
8. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
[TBL] [Abstract][Full Text] [Related]
9. Monitoring fondaparinux with the Sonoclot.
Nilsson CU; Engström M
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):619-22. PubMed ID: 17890948
[TBL] [Abstract][Full Text] [Related]
10. Test of the month: The chromogenic antifactor Xa assay.
Gehrie E; Laposata M
Am J Hematol; 2012 Feb; 87(2):194-6. PubMed ID: 22081480
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
12. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
Katagiri H; Itoh S; Uchida T; Kawai Y; Watanabe K
Rinsho Byori; 1999 Nov; 47(11):1046-51. PubMed ID: 10590682
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.
Mahieu E; Claes K; Jacquemin M; Evenepoel P; Op De Beek K; Bogaert AM; Kuypers D; Verhamme P; Meijers B
Artif Organs; 2013 May; 37(5):482-7. PubMed ID: 23461610
[TBL] [Abstract][Full Text] [Related]
14. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
15. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
16. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
[TBL] [Abstract][Full Text] [Related]
17. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels.
Jeske WP; Walenga JM; Samama MM; Hoppensteadt D; Mayuga M; Fareed J
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):206-10. PubMed ID: 21297455
[TBL] [Abstract][Full Text] [Related]
18. Anti-Xa monitoring: inter-assay variability.
Depasse F; Gilbert M; Goret V; Rolland N; Samama MM
Thromb Haemost; 2000 Dec; 84(6):1122-3. PubMed ID: 11154127
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetics of fondaparinux administered at prophylactic doses after major orthopaedic surgery in everyday practice.
Delavenne X; Zufferey P; Baylot D; Nguyen P; Borg JY; Fontenay M; Deygas B; Mismetti P; Laporte S; ;
Thromb Haemost; 2010 Aug; 104(2):252-60. PubMed ID: 20539905
[TBL] [Abstract][Full Text] [Related]
20. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing.
Smogorzewska A; Brandt JT; Chandler WL; Cunningham MT; Hayes TE; Olson JD; Kottke-Marchant K; Van Cott EM
Arch Pathol Lab Med; 2006 Nov; 130(11):1605-11. PubMed ID: 17076521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
